Inna Chen1, Torben Lorentzen2, Dorte Linnemann3, Christian Pállson Nolsøe2, Bjørn Skjoldbye2, Benny V Jensen1, Dorte Nielsen1. 1. a Department of Oncology , Herlev Hospital, Copenhagen University Hospital , Herlev , Denmark . 2. b Department of Surgical Gastroenterology , Herlev Hospital, Copenhagen University Hospital , Herlev , Denmark , and. 3. c Department of Pathology , Herlev Hospital, Copenhagen University Hospital , Herlev , Denmark.
Abstract
BACKGROUND: Neoplasm seeding is a serious complication after liver metastases biopsy. Reported incidences vary between 10% and 19% for colorectal cancer (CRC) and are unknown for breast cancer (BC). The aim of this retrospective study was to determine the frequency of tumor seeding after ultrasound-guided percutaneous biopsy of CRC and BC liver metastases. MATERIAL AND METHODS: Unselected liver biopsies performed in the period of 2005-2012 at our institution were extracted from the National Pathology Registry. Medical records including imaging from patients with biopsy-verified BC and CRC liver metastases were retrospectively reviewed. The endpoint was the development of abdominal wall recurrence following liver biopsy. RESULTS: Of total 2981 biopsies we identified 278 patients with CRC and 155 patients with BC biopsy-verified liver metastases. During the median follow-up of 25 months after biopsy (range 3-253 months), no seeding was recorded in patients with BC. Within the median follow-up of 34 months (3-111 months), seeding was registered in 17/278 (6%) of patients with CRC; three patients of 278 (1%) had undoubtedly biopsy-related seeding, which became apparent six, nine, and 26 months after biopsy, respectively; and in nine patients (3%) seeding occurred due to either biopsy or other interventions; and five patients had seeding, which were assessed as a consequence of other invasive procedures than biopsies. The median overall survival of the 17 patients with seeding was 70 months compared to 39 months of patients without seeding. CONCLUSIONS: The results showed no seeding in BC patients. Seeding rate after biopsy in CRC patients is not negligible, however, without affecting outcome.
BACKGROUND:Neoplasm seeding is a serious complication after liver metastases biopsy. Reported incidences vary between 10% and 19% for colorectal cancer (CRC) and are unknown for breast cancer (BC). The aim of this retrospective study was to determine the frequency of tumor seeding after ultrasound-guided percutaneous biopsy of CRC and BC liver metastases. MATERIAL AND METHODS: Unselected liver biopsies performed in the period of 2005-2012 at our institution were extracted from the National Pathology Registry. Medical records including imaging from patients with biopsy-verified BC and CRC liver metastases were retrospectively reviewed. The endpoint was the development of abdominal wall recurrence following liver biopsy. RESULTS: Of total 2981 biopsies we identified 278 patients with CRC and 155 patients with BC biopsy-verified liver metastases. During the median follow-up of 25 months after biopsy (range 3-253 months), no seeding was recorded in patients with BC. Within the median follow-up of 34 months (3-111 months), seeding was registered in 17/278 (6%) of patients with CRC; three patients of 278 (1%) had undoubtedly biopsy-related seeding, which became apparent six, nine, and 26 months after biopsy, respectively; and in nine patients (3%) seeding occurred due to either biopsy or other interventions; and five patients had seeding, which were assessed as a consequence of other invasive procedures than biopsies. The median overall survival of the 17 patients with seeding was 70 months compared to 39 months of patients without seeding. CONCLUSIONS: The results showed no seeding in BC patients. Seeding rate after biopsy in CRC patients is not negligible, however, without affecting outcome.
Authors: Kim Sivesgaard; Lars P Larsen; Michael Sørensen; Stine Kramer; Sven Schlander; Nerijus Amanavicius; Arindam Bharadwaz; Dennis Tønner Nielsen; Frank Viborg Mortensen; Erik Morre Pedersen Journal: Eur Radiol Date: 2018-05-07 Impact factor: 5.315
Authors: Nicos Fotiadis; Katja N De Paepe; Lawrence Bonne; Nasir Khan; Angela Riddell; Nicholas Turner; Naureen Starling; Marco Gerlinger; Sheela Rao; Ian Chau; David Cunningham; Dow-Mu Koh Journal: Eur Radiol Date: 2020-07-14 Impact factor: 5.315
Authors: Felix G Gassert; Johannes Rübenthaler; Clemens C Cyran; Johann S Rink; Vincent Schwarze; Johanna Luitjens; Florian T Gassert; Marcus R Makowski; Stefan O Schoenberg; Marius E Mayerhoefer; Dietmar Tamandl; Matthias F Froelich Journal: Eur J Nucl Med Mol Imaging Date: 2021-03-09 Impact factor: 9.236